REGARDING SODIUM AMYTAL AS A PROGNOSTIC AID IN INSULIN AND METRAZOL SHOCK THERAPY OF MENTAL PATIENTS. (DEMENTIA PRÆCOX.)
Abstract
1. A total of 55 cases of dementia præcox were tested by the intravenous injection of prenarcotic doses of sodium amytal prior to treatment with insulin hypoglycemic therapy.
2. An ameliorating response to the injection of sodium amytal was obtained in 30 patients and of these 23 or 77 per cent had a favorable therapeutic response to insulin hypoglycemic treatment.
3. No ameliorating response to sodium amytal was obtained in 25 cases and of these 16 or 64 per cent failed to respond to insulin treatment.
4. The results of metrazol convulsant therapy in cases that failed to respond to insulin treatments are also compared with the sodium amytal test.
5. The response to the sodium amytal test appears to be of prognostic value in insulin hypoglycemic shock therapy.
6. Plans for further studies are indicated.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
